Nancy Uan-Tsin Lin MD

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Associate Chief, Division of Breast Oncology Center, Dana-Farber Cancer Institute

Join to view full profile

44 Binney St# Dana-FarBoston, MA 02115
Phone+1 617-632-3800
Fax+1 617-632-1930

Dr. Lin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2002 - 2027
VT State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2007 May 14
COMPLETED
PHASE2
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
COMPLETED
PHASE1
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
TERMINATED
PHASE2

Publications & Presentations

PubMed

Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer.
Dario Trapani, Sachin Kumar Deshmukh, Sharon Wu, Joanne Xiu, Priya Jayachandran
Breast. 2026-08-12
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label...
Shanu Modi, Rashmi K Murthy, A Jo Chien, Nancy U Lin, Nicholas P McAndrew
Clinical Breast Cancer. 2026-08-01
Intracranial progression-free survival correlates with overall survival and varies by tumor subtype in patients with breast cancer and brain metastases.
Sarah L Sammons, Ryan Shanley, Carey K Anders, Nancy U Lin, Paul W Sperduto
Neuro-Oncology. 2026-08-01

Journal Articles

Attitudes of Patients with Metastatic Cancer Towards Research Biopsies
Nancy Lin, MD, Asia‐Pacific Journal of Clinical Oncology

Press Mentions

CBD Trial Shows Promise for Cancer Anxiety ReliefDecember 17th, 2024
Managing Central Nervous System Metastasis in Patients with HER2-Positive Breast CancerOctober 22nd, 2024
T-dXd Demonstrated Intracranial Activity in HER2+ Breast CancerOctober 5th, 2024